Gonik B
Department of Obstetrics, Gynecology, and Reproductive Sciences, University of Texas Medical School, Houston.
Clin Ther. 1992 Jan-Feb;14(1):83-9.
A prospective, multicenter, open-label randomized trial was conducted to compare the efficacy and tolerability of imipenem-cilastatin (I-C) monotherapy with clindamycin+aminoglycoside (C+A) combination therapy. Forty-nine patients were able to be evaluated for clinical efficacy in the treatment of postpartum endometritis. Twenty-three patients received I-C and 26 received C+A therapy. The two groups were statistically similar for demographic and clinical variables upon entry into the study. The results of therapy were categorized as cured, improved, or failed. The use of I-C resulted in an overall clinical response rate (cured and improved) of 91%, compared with an overall response rate with C+A of 73% (P = 0.15). Patients categorized as improved comprised 56.5% of those in the I-C group and 38.5% of those in the C+A group. Patients categorized as failed comprised 8.7% of those in the I-C group and 26.9% of those in the C+A group. Overall, these data support the use of I-C for the treatment of appropriate patients with postpartum endometritis.
进行了一项前瞻性、多中心、开放标签的随机试验,以比较亚胺培南-西司他丁(I-C)单药治疗与克林霉素+氨基糖苷类(C+A)联合治疗的疗效和耐受性。49例患者能够接受产后子宫内膜炎治疗的临床疗效评估。23例患者接受I-C治疗,26例接受C+A治疗。进入研究时,两组在人口统计学和临床变量方面在统计学上相似。治疗结果分为治愈、改善或失败。I-C治疗的总体临床缓解率(治愈和改善)为91%,而C+A的总体缓解率为73%(P=0.15)。在I-C组中,改善的患者占56.5%,在C+A组中占38.5%。在I-C组中,失败的患者占8.7%,在C+A组中占26.9%。总体而言,这些数据支持使用I-C治疗合适的产后子宫内膜炎患者。